(VIANEWS) – Shares of Biogen (NASDAQ Composite: BIIB) fell by a staggering 100.6% in 30 days from $265 to $-1.59 at 18:34 EST on Monday, after two consecutive sessions in a row of losses. NASDAQ Composite is rising 0.45% to $15,993.71, following the last session’s downward trend.
Biogen’s last close was $242.90, 48.16% below its 52-week high of $468.55.
Today’s last reported volume for Biogen is 947707 which is 11.65% below its average volume of 1072728.
The company’s growth estimates for the current quarter and the next is a negative 53.3% and a negative 25.1%, respectively.
Year-on-year quarterly revenue growth declined by 24.6%, now sitting on 11.7B for the twelve trailing months.
Biogen’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.27%, a negative 0.50%, and a positive 1.30%, respectively.
Biogen’s highest amplitude of average volatility was 1.79% (last week), 1.34% (last month), and 1.30% (last quarter), respectively.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
Biogen’s stock is considered to be overbought (>=80).
Biogen’s Stock Yearly Top and Bottom Value
Biogen’s stock is valued at $-1.59 at 18:34 EST, way below its 52-week low of $238.40.
Biogen’s Moving Average
Biogen’s worth is way under its 50-day moving average of $277.76 and way below its 200-day moving average of $312.48.
More news about Biogen (BIIB).